



# Supplementary Figure S1


## patient 1




## patient 2




## patient 3




## patient 4




## patient 5







# Supplementary Figure S2



# Supplementary Figure S3




# Supplementary Figure S4




# Supplementary Figure S5


**a** Single cell dataset GEO: GSE160244  
PC9 xenograft tumors with Osimertinib




**b** ● Cancer cells (0-6,9,10,12-14,17,18)  
● Fibroblasts (active) (8,11)  
● Fibroblasts (inactive) (15)  
● Macrophages (7)  
● Leukocyte cells (16)



**c** Control Osimertinib




**d** Color Key and Histogram  
Drug perturbations signal  
Row Z-Score




**e** ● Cancer cells  
● Fibroblasts (active)  
● Fibroblasts (inactive)  
● Macrophages  
● Leukocyte cells  
Average  
Percent



**f** Top 20 pathways enriched  
-log10(P)



# Supplementary Figure S6



# Supplementary Figure S7

## MCL clusters

